Search
"Hordes of cash by Big Pharma and the larger biotech companies have
accumulated, and now that healthcare reform is behind us, they've got a
bit more confidence, and they want to fill in their pipeline and be in
control of the FDA process," says Joel Papernik, a partner at Mintz Levin
in The Deal's video. "They have a lot of motivation to buy right now," including the expiration of many patents, he says. The interview with Papernik is part of our special series on Faces of the Middle Market. Read the full story in The Deal magazine, watch the videos, listen to the podcasts and read the white papers. Watch the interview with Papernik below or download it on iTunes. - Mary Kathleen Flynn
